Rigel’s R289 Secures the US FDA’s Fast Track Designation for Treating Lower-Risk Myelodysplastic Syndrome
Shots:
- The US FDA grants Fast Track Designation to R289 in patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS)
- The P-Ib study is currently assessing the safety, tolerability, pharmacokinetics & preliminary efficacy of R289 among patients with r/r lower-risk MDS, with recruitment underway
- R289 (prodrug of R835) is an IRAK1/4 dual inhibitor that works by blocking inflammatory cytokine production in response to TLR and IL-1R signaling. Dysregulation of these pathways contributes to inflammatory conditions
Ref: Rigel Pharmaceuticals | Image: Rigel Pharmaceuticals
Related News:- MD Anderson Cancer Center and Rigel Pharmaceuticals Collaborate to Advance Evaluation of Olutasidenib in Hematologic Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
